CStone PharmaceuticalsCSPHF -14.46%38 Days Payable is 342.04 as of Dec. 2025, which is 46% below its 10-year median of 633.01. GuruFocus rates CSPHF with a GF Score™ of 38/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 705 Biotechnology companies, CStone Pharmaceuticals ranks better than 73.05% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPHF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, CStone Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CStone Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where CStone Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CStone Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CStone Pharmaceuticals (CSPHF) has a Days Payable of 342.04 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CStone Pharmaceuticals and its competitors. This is 46% below median its historical median of 633.01. Over the past decade, CStone Pharmaceuticals' Days Payable has ranged from 47.66 to 754.09. According to the industry distribution chart, CStone Pharmaceuticals ranks #190 out of 705 companies in the Biotechnology industry, placing it in the top 27%.
Is CStone Pharmaceuticals' Days Payable too high?
CStone Pharmaceuticals' current Days Payable of 342.04 is 46% below median its 10-year median of 633.01. Over the past 10 years, this metric has ranged from a low of 47.66 to a high of 754.09. The Biotechnology industry median Days Payable is 113.36. CStone Pharmaceuticals' value of 342.04 is 201.7% above this industry median. Based on the distribution chart, CStone Pharmaceuticals ranks #190 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CStone Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CStone Pharmaceuticals ranks #190 out of 705 companies for Days Payable. This puts CStone Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 113.36. CStone Pharmaceuticals' value of 342.04 is 201.7% above this benchmark. Historically, CStone Pharmaceuticals' own Days Payable has ranged from 47.66 to 754.09 over the past decade. While the company's 10-year median is 633.01 vs. the industry median of 113.36, CStone Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CStone Pharmaceuticals's current Days Payable of 342.04 is 201.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CStone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CStone Pharmaceuticals's current Days Payable is 342.04, which is 46% below median its own 10-year median of 633.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.59 — trading 296.3% above its estimated fair value. The current Days Payable is 342.04, which is 46% below median its 10-year median of 633.01 and 201.7% above the Biotechnology industry median of 113.36. CStone Pharmaceuticals' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Days Payable is 342.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?
Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.59 is trading 296.3% above its estimated GF Value™ of $0.15.
GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CSPHF:
Days Payable: 342.04 (46% below median its 10-year median of 633.01)
GF Value™: $0.15 vs. price of $0.59 (296.3% above fair value)
Industry Position: 201.7% above the Biotechnology median (#190 of 705)
No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
38GF Score
Get the complete analysis for CSPHF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPHF has been successfully added to your 
